Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus
Anticancer Research · 2025
DOI: 10.21873/anticanres.17868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yoshihiro Amano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan. Hauptthemen laut MEDLINE: Irinotecan, Everolimus, Small Cell Lung Carcinoma, Neovascularization, Pathologic.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
- Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan okimoto@med.shimane-u.ac.jp.
Zitieren
APA
Amano, Y., Tanino, R., Sun, R., Tsubata, Y., Isobe, T., & Okimoto, T. (2025). Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus. Anticancer Research. https://doi.org/10.21873/anticanres.17868
Vancouver
Amano Y, Tanino R, Sun R, Tsubata Y, Isobe T, Okimoto T. Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus. Anticancer Research. 2025. doi:10.21873/anticanres.17868
BibTeX
@article{Amano2025,
author = {Amano, Yoshihiro and Tanino, Ryosuke and Sun, Rong and Tsubata, Yukari and Isobe, Takeshi and Okimoto, Tamio},
title = {Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17868}
}
EUVIMED